"you’d imagine there could be potentially many large pharma who would like to either get a cut of Efti each time it was sold as a potential SOC or combine there drug to potentially improve the efficacy or a combination of both".
Wouldn't that involve many more years of trials though?..
My concern today is that Merck can drag this out for a few years while their Keytruda patents are still live. They have no hurry (other than seeing many more survivors) to spend a few billion dollars in aquisition.
Overnight Market report, page-2232
-
- There are more pages in this discussion • 706 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
29.8¢ |
Change
0.008(2.59%) |
Mkt cap ! $432.7M | |||
| Open | High | Low | Value | Volume |
| 29.0¢ | 30.0¢ | 29.0¢ | $235.3K | 798.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 38240 | 29.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 30.0¢ | 296260 | 16 |
View Market Depth
| Last trade - 10.46am 11/11/2024 (20 minute delay) ? |
| IMM (ASX) Chart |